Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 4, 2008

Deerfield Bankrolls Vivus’ Late-Stage ED Treatment with $30M

  • Deerfield Management will invest $30 million in Vivus to help the company further its erectile dysfunction drug avanafil. The treatment is a fast-acting, highly selective, phosphodiesterase type 5 inhibitor (PDE5i) and is in a Phase III study.

    Deerfield will provide $20 million under a royalty and funding agreement in the first 18 months. Deerfield will receive a royalty on sales of Muse, Vivus' marketed ED treatment, and avanafil if approved. Deerfield will also tender $10 million from the sale of Vivus’ common stock.

    “The market for ED therapies continues to grow. In 2007, sales of all PDE5i’s exceeded $3 billion, an increase of 15% over the previous year,” according to Leland Wilson, president and CEO of Vivus.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »